Greater patient selection may be needed for first line nivolumab to improve progression-free survival in advanced lung cancer
This item is under embargo and is only visible to journalists
Please login here
Regions: Europe, Belgium, Denmark, Switzerland, North America, United States
Keywords: Health, Medical
The item has been withdrawn. If you are a journalists please contact the person that posted the item with any questions.